

Q2 2021 results

28 July 2021

Cautionary statement regarding forward-looking statements



This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2020 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our second quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020.

All expectations and targets regarding future performance and the dividend should be read together with the section "Outlook, assumptions and cautionary statements" on pages 68 and 69 of our second quarter 2021 earnings release.





Q2 2021 progress

Growth drivers

Q2 2021 financial results

Q&A

Emma Walmsley

Luke Miels Deborah Waterhouse Dr. Hal Barron Brian McNamara

Iain Mackay

Roger Connor David Redfern



Q2 2021 progress

Emma Walmsley

Q2 2021: Strong financial performance and execution of strategic priorities

Strong Q2 financial performance: Sales +15%; Adjusted EPS +71% CER

Double-digit growth in New and Specialty Pharma and Vaccines

Good growth in Consumer Healthcare

Confident in delivering FY 2021 Adjusted EPS guidance

R&D delivers LA Cab PrEP filing and positive headline daprodustat results

BD strengthens pipeline in HIV, immuno-oncology, immuno-neurology^

Focused on delivering new growth outlooks and maximising value to shareholders

Progress made across all strategic priorities in Q2



Innovation	Positive Ph2/3 data: daprodustat COVID vaccines	Approvals/opinions: Benlysta LN and sotrovimab	Submissions: Rolling NDA for LA cabotegravir PrEP	
	Vation ViiV/Halozyme: ultra long-acting HIV medicines		GSK/Alector^: AL001 & AL101 neurodegeneration	
Performance	New and Specialty Pharma products +25% Q2, +14% H1	Lead indicators position Shingrix for recovery in US	6 of 9 CH power brands growing double-digit	
Trust	MSCI AA rating	Principal Partner COP26	>1bn toothpaste tubes recyclable by 2025	
— Culture —		Alector transaction subject to	HSR clearance; all growth rates at CER	

Priority is to unlock potential and maximise value for shareholders





¹ All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. 2021-26 CAGR is for the 5 years to 2026, using 2021 as the base year *Sales including Brands divested / under review, £9.5bn Continuing sales; **CER Proforma excluding brands divested/under review; ^Consumer Healthcare operating margin; ^*Therapeutic Oral Health, Pain Relief, Respiratory, Vitamins, Minerals, and Supplements and Digestive Health. All expectations and targets regarding future performance should be read together with the "Outlook, assumptions and cautionary statements" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation




Growth drivers

Luke Miels Deborah Waterhouse Dr. Hal Barron Brian McNamara

Shingrix: strong underlying demand supports confidence in recovery



Volumes increasing as individuals complete COVID-19 vaccination series



US NBRx¹ and COVID-19 vaccination in 50+²

- Individuals 50+ fully vaccinated for COVID-19
- US: ~50% eligible patients expect to receive Shingrix within 1-3 months following COVID series completion³
 - Nearly 80% of adults 50+ now fully vaccinated for COVID²
 - NBRx volume +73% from start of Q2 2021 to end of quarter¹
 - Implementing strong, multi-channel DTC; maximising retailer engagement
- Germany: scripts improving as adults complete COVID series

US recovery on track for H2 2021




- Q2 2021: Global sales £295m +1% CER vs Q2 2020, reflecting challenging comparator period
 - US: TRx volume +77% vs Q2 2020
- Unconstrained supply to support US recovery and geographic expansion; availability expected in 16 countries by end 2021
- FDA approval received in 18+ immunocompromised population

Shingrix 50+ NBRx volume

^{1.} NBRX: IQVIA New to Brand Weekly data (18/6) 2. CDC (<u>https://covid.cdc.gov/covid-data-tracker/#vaccinations</u>) 3. Market research ATU May 2021

Recent oncology launches contributing to growth





Zejula: US 1LM share grows despite COVID environment^{1,2}

- Q2 sales £98m, +38% CER despite 20% decrease in OC diagnosis²
 - Delayed surgeries impact new patient starts ~6 months after
 - Expect impact until OC diagnosis returns to pre-pandemic levels
- 59%² new patients going on a PARPi receive Zejula
- Watch-and-wait in 1LM decreased to 57%¹ with improved patient awareness
- Initiated Phase 3 study in ctDNA+ HER2- breast (ZEST); data 2025

Blenrep: demand shifting to earlier lines with US community oncologists³




Robust clinical program in place to optimize opportunity

3L/4L+: 36k patients ⁴	2L: 42k patients ⁴	Major Commercial Opportunity			
DREAMM-3: mono vs. pom/dex; Pivotal data 1H22	DREAMM-7: combo w/ bor/dex, dose based on DREAMM-6; Pivotal Data 2H23				
DREAMM-4: combo w/ pembro; Pilot data 1H22	DREAMM-8: combo ALGONQUIN; Pivota	w/ pom/dex, dose based on al data 2H22			
	1L: 67k patients ⁴	Lower Probability of Success			
DREAMM-5: platform pilot trial; GSI combo data 2H21	DREAMM-9: combo expected 2H22	w/ bor/len/dex; Pilot data			

HIV: Delivering sustainable growth





Dovato switch* continues to grow strongly

- Q2 sales (+14%) more than offsetting Q1 decline
- Half year growth of +1% across HIV portfolio
- Commercial execution driving performance in Dovato
- Early positive launch signals for Cabenuva
- Cabotegravir PrEP filing with FDA completed

Compelling data presented at IAS Congress

Dovato:

- 48 week data for SALSA study demonstrate comparable efficacy and safety vs broad range of 3DRs, reinforcing Dovato use in a switch setting
- 48 week data for STAT study demonstrate applicability of Dovato as a first-line regimen in a rapid Test and Treat model of care

Cabenuva:

 1 year data for CUSTOMIZE study identifies how to integrate Cabenuva into US healthcare practices; revealed patient preference over daily oral

Cabotegravir for prevention (PrEP):

 Virology and efficacy results from HPTN 084 suggest predicted efficacy over one year follow-up of 91% for CAB-LA vs 15% for daily oral FTC/TDF

^{*} Source: IQVIA (R4W) and ActOne (R3M)

daprodustat: potential to be best in class for anaemia of chronic kidney disease





- Five phase III studies
- >8,000 patients treated for up to 3.75 years
- Dialysis/ non-dialysis and incident dialysis patients
- Trial design aligned with global regulators
- Single haemoglobin target
- No meta-analysis required

All five studies met primary efficacy endpoint

Non-inferior vs erythropoietin in risk of MACE in both dialysis and non-dialysis

Full data to be presented at a forthcoming medical meeting

MACE: Major Adverse Cardiovascular Events

ASCEND ND and ASCEND D co-primary endpoints: Safety: MACE: All cause mortality, non-fatal MI, and non-fatal stroke; Efficacy mean change in haemoglobin from baseline For trial summaries see: https://www.gsk.com/media/7048/clinical-trials-summary.pdf

Three significant business development transactions in Q2





Two clinical stage potential first-inclass mAbs for neurodegenerative diseases*

Progranulin elevating mAbs: AL001, and AL101

Progranulin is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative diseases

AL001: FTD-GRN phase III recruiting

 Updated Phase 2 data to be presented AAIC, 29 July

AL101: (Phase 1) for development in more prevalent neurodegenerative diseases (PD, AD)



anti-TIGIT enabling novel nextgeneration IO combinations

EOS448/GSK '859 Phase 1 dose escalation and anti-PD1 combination studies ongoing

Complements existing IO portfolio targeting the CD226 axis:

- CD96: GSK'608 (collaboration with 23andMe); Phase 1 ongoing
- anti-PVRIG: GSK'562 FTIH 2022



ENHANZE® drug delivery technology to enable development of "ultra longacting" medicines for HIV

Exclusive license for four HIV medicine targets

 Potential in PrEP to increase cabotegravir dosing interval from every two months to up to six months

R&D focus on science of the immune system, human genetics and advanced technologies

FTD-GRN: frontotemporal dementia related to a mutation in the progranulin gene; PD, Parkinson's disease; AD, Alzheimer's disease; IO, immuno-oncology; PrEP, pre-exposure prophylaxis AAIC: Alzheimer's Association International Conference, 26-30 July, Denver FTIH: First time in Human

^{*} Pending Hart-Scott Rodino (HSR) clearance

Significant upcoming R&D data points in next 18 months



H2 2021 data readou	ts: Specialty	Select pivotal data in 2022: Specialty and Vaccines	
daprodustat Anaemia of CKD	ASCEND Phase 3	Blenrep: DREAMM-3H1 20223L multiple myelomaH1 2022	
Blenrep r/r multiple myeloma	GSI combination cohort	Blenrep: DREAMM-8 2L multiple myelomaH2 2022	
H2 2021 data readou	ts: COVID solutions	otilimab: contRAst H2 2022 Rheumatoid arthritis	
Medicago Vaccine	Phase 3	MenABCWY vaccine H2 2022	
Sanofi (vidprevtyn)	Phase 3	Meningococcal disease	
Vaccine		RSV older adults H2 2022	
otilimab MAb therapeutic	OSCAR Phase 2 extension	RSV prophylaxis	
sotrovimab MAb therapeutic	Phase 2 COMET- PEAK (IM)	RSV maternal H2 2022RSV prophylaxisH2 2022	

CKD: Chronic Kidney Disease; GSI: Gamma Secretase Inhibitor; Mab, monoclonal antibody; 1L: First line treatment, 2L second line, 3L third line. r/r: relapsed/refractory

Consumer Healthcare

Q2 Revenue +7%¹, strong underlying category performance

Q2 Performance

- Continuing sales¹ Q2 +7% vs flat Q2 20²:
 - 2% drag from systems cutover benefit in Q2 prior year
 - strong performance in most categories
- Q2 2 year CAGR³ +3% and up +4% excluding seasonal cold flu and nasal products
- Ecommerce⁴ 7% sales up c.30%
- 6 of the 9 power brands gained or held share, with 6 power brands reporting double digit growth
- Emerging markets continuing sales increased double digit
- FY21 sales outlook unchanged

¹ CER sales excluding	g brands	divested/under	review
----------------------------------	----------	----------------	--------

- ² CER Pro-forma sales excluding brands divested/under review
- ³2 year CAGRS calculated using 2020 CER Pro-forma sales excluding brands divested/under review ⁴ YTD May





Consumer Healthcare On track to create leading global consumer healthcare company



Key Milestones

- Divestment program completed in Q1 21 with sales from brands divested under review in Q2 £33m (vs £116m Q2 20) and H1 £84m (vs £380m H1 20)
- Integration: On track
 - Commercial now fully complete
 - 3 major manufacturing sites (Guayama, Aprilia & Suzhou) transitioned to GSK systems, remaining site transitions on track
- 2022 guidance¹ retained:
 - £500m annual synergies
 - Mid to high 20s percent adjusted operating margin²

¹ As shared 19 December 2018 in the press release announcing the GSK and Pfizer Joint Venture

² At 2017 constant exchange rates



Q2 2021 results

Iain Mackay

Headline results



	Q2 2021	Reported %			H1 2021	Reported %	
	£m	AER	CER		£m	AER	CER
Turnover	8,092	6	15		15,510	(7)	(1)
Total operating profit	1,675	(41)	(30)		3,368	(31)	(21)
Total EPS	27.9p	(39)	(28)		49.4p	(36)	(27)
Adjusted operating profit	2,158	23	43		4,039	(9)	3
Adjusted EPS	28.1p	46	71		51.0p	(10)	2
Free cash flow	316	(84)	n/a	-	313	(87)	n/a

Results reconciliation Q2 2021




	Total results	Intangible amortisation	Intangible impairment	Major restructuring	Transaction related	Disposals, significant legal and other	Separation costs	Adjusted results
Turnover (£bn)	8.1							8.1
Operating profit (£bn)	1.7	0.2	< 0.1	0.1	0.1	(0.1)	0.1	2.2
EPS (pence)	27.9	3.2	0.1	2.1	0.5	(6.9)	1.2	28.1
Q2 20 EPS (pence)	45.5	3.2	1.9	2.9	4.1	(38.7)	0.3	19.2

Group sales and adjusted operating margins Q2 2021




Sales





Adjusted operating margin



Charts may not sum due to rounding

Adjusted operating profit to net income


Continued delivery of financial efficiency



	2Q20	2Q21
	£m	£m
Operating profit	1,749	2,158
Net finance expense	(227)	(185)
Share of associates	19	16
Тах	(316)	(366)
Tax rate	20.5%	18.4%
Non-controlling interests	(267)	(216)
Net income	958	1,407

Free cashflow of £0.3bn





CCL: contingent consideration liability


RAR: Returns and rebates

* Net Capex includes purchases less disposals of property, plant and equipment and intangibles

** Net operating cash is net cash inflow from operating activities including changes in working capital, excluding restructuring, operating CCL, and significant legal payments

*** Other includes significant legal payments, net interest paid, income from associates and JVs and distributions to minorities





(+)New and Specialty growth Favourable comparator due to (+)destocking in Q2 2020 Favourable US return and rebate (+)adjustments **Operating profit factors** Operating leverage from higher sales (+)Continued cost control (+)

R&D investment

Sales factors

29.3%

1,241


2Q21












Sales factors

Pandemic adjuvant sales (+)(+)Paediatric and adolescent demand COVID-19 vaccination programme (-)impact on routine adult vaccination

Operating profit factors




Meningitis programmes


Consumer Healthcare Q2 2021



Sales All figures £m Q2 2021 Total : £2,292m: +3% CER; -4% AER +7% CER -1% AER 2,273 2,259 639 663 529 563 214 210 -70% CER 404 359 -72% AER 487 464 116 33 2Q21 2Q20 2Q21 2Q20 VMS Oral health Pain relief Digestive health and other Brands divested/under review Respiratory health



Sales factors







Group H1 performance	Group Q3 considerations	Group Q4 considerations
Sales £15,510m, -1% CER Adj OP £4,039m, +3% CER Adj EPS 51.0p, +2% CER, including +7% contribution from COVID-19 solutions	Unfavourable year-on-year comparators in R&D and SG&A due to Q3 2020 one-time benefits	Adj EPS growth in H2 to be weighted to Q4

FY guidance: Adj EPS to decline mid-to-high single-digit percentage at CER (excl. COVID-19 solutions)

COVID-19 solutions: £276m sales C

COVID-19 solutions:

Pursuing further contracting for pandemic adjuvant and sotrovimab

COVID-19 solutions expected to contribute approximately between 4% to 6% of Adj EPS growth at CER

* All expectations and targets regarding future performance should be read together with the "Outlook, assumptions and cautionary statements" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation; all figures at constant exchange rates (CER). Adj = Adjusted



Q&A session



Appendix





Adj EPS/Dividend

Adj EPS guidance:

Mid to high-single digit decline at CER, excluding COVID-19 solutions COVID-19 solutions expected to contribute approximately 4% to 6% to growth at CER **Dividend:**

Expect 80p for 2021

Pharmaceuticals

Turnover:

Flat to low-single digit growth for total Pharma, excluding divestments and COVID-19 solutions High-single digit decline for Established Pharma

Adj operating costs

Adj SG&A and R&D:

Tight cost control, with targeted investments, and restructuring benefits R&D investment to grow around 10% in 2021

Vaccines

Turnover:

Broadly flat, excluding pandemic adjuvant sales Strong H2 global Shingrix performance expected with potential for slight full year growth Flu global volumes to be broadly similar, without RAR benefit seen in 2020 Meningitis broadly flat, with pandemic impact Established Vaccines to experience similar pressures as in 2020, largely informed by pandemic dynamics

Other Adj financials

Royalties:

Between £300-350m Net finance expense: Between £800-850m Effective Tax rate: Around 18%, excluding possible US tax reform

Consumer Healthcare

Turnover:

Low to mid-single digit growth for Consumer excluding brands divested/under review; outperforming the market Sales of brands divested/under review to be around £150m

Across the Group, our turnover comments assume that healthcare systems and consumer trends approach normality in the second half of 2021; all turnover and growth comments at CER; Adj = Adjusted

All expectations and targets regarding future performance should be read together with the "Outlook, assumptions and cautionary statements" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation

Expected costs and savings under Major Restructuring Programmes & Consumer Separation



	Date	£bn	Cumulative Actuals to	H1 2021	2021	2022	2023	
	Announced	2021 Average Rates	Actuals to 2020	Actuals		Projected	1	Total Lifetime
2018		Savings ²	0.3	0.4	0.5			0.5
Restructuring Programme	Q2'18	Total charges	1.5	-	0.1			1.6
(Incl. Tesaro)		Cash payments	0.3	0.1	0.2	-		0.5
		Synergies ²	0.3	-	0.4	0.5		0.5
Consumer JV	Dec-18	Total charges	0.6	-	0.2	-		0.8
		Cash payments	0.5	0.1	0.1	0.1		0.7
Conception		Savings ²	0.1	-	0.4	0.8	1.0	1.0
Separation Preparation	Feb-20	Total charges	0.8	0.2	1.1	0.5	-	2.4
Programme		Cash payments	0.2	0.2	0.6	0.7	0.1	1.6
		Total charges	0.1	0.1	0.3	0.2	-	0.6
Separation Cos	sts	Cash payments	0.1	0.1	0.3	0.2	-	0.6

¹ All expectations and targets regarding future performance should be read together with the "Outlook assumptions and cautionary statement" sections of the Second Quarter 2021 Results Announcement and the cautionary statement slide included with this presentation

² Savings and synergies shown are cumulative for the programme to date throughout the table ³ Excludes Capex

Our R&D pipeline 63 potential vaccines and medicines



Phase I

C. difficile* vaccine
Klebsiella pneumoniae* vaccine
MenABCWY (2 nd gen) vaccine
SAM (COVID-19 model) vaccine
SAM (rabies model) vaccine
BVL-GSK098* (ethionamide booster) tuberculosis
VIR-2482* (neutralizing monoclonal antibody) influenza
2556286* (Mtb inhibitor) tuberculosis
3186899*2 (CRK-12 inhibitor) visceral leishmaniasis
3494245* (proteasome inh) visceral leishmaniasis
3882347* (FimH antagonist) uUTI
3923868 (PI4kβ inhibitor) viral COPD exacerbations
4182137* (VIR-7832) COVID-191
3739937 (maturation inhibitor) HIV
feladilimab* (3359609, ICOS agonist) multiple myeloma
3326595* (PRMT5 inhibitor) cancer
3368715* (Type 1 PRMT inhibitor) cancer
3745417 (STING agonist) cancer
3845097* (NY-ESO-1/TGFbR2 TCR T) cancer
3901961* (NY-ESO-1/CD8a TCR T) cancer
4074386* (TSR-033, LAG3 antagonist) cancer
4362676* (Mat2A inhibitor) cancer
4428859*4 (EOS-448, TIGIT antagonist) cancer
6097608* (CD96 antagonist) cancer
AL101*4 (anti-sortilin) neurodegenerative disorders
2982772 (RIP1-k) psoriasis
3858279* (CCL17 inhibitor) osteoarthritis pain
3915393* (TG2 inhibitor) celiac disease
2798745* (TRPV4 blocker) diabetic macular edema

Phase II

COVID-19 (Sk	K Bioscience)* [#] vaccine
Malaria (fract	ional dose)* vaccine
S. aureus*1 va	accine
Shigella* vaco	cine
Therapeutic H	HBV*1 vaccine
bepirovirsen*	* (3228836, HBV ASO) HBV
3036656* (leu	cyl t-RNA inhibitor) tuberculosis
3640254 (mat	turation inhibitor) HIV
3810109* (bro	oadly neutralizing antibody) HIV
bintrafusp alf	fa* (TGFβ trap/anti-PDL1) biliary tract cancer**
cobolimab* (1	TSR-022, TIM-3 antagonist) NSCLC
linerixibat (IB	ATi) cholestatic pruritus in primary biliary cholangitis

Phase III/Registration

Bexsero infants (US) vaccine
COVID-19 (Medicago)*1 vaccine
COVID-19 (Sanofi)*1 vaccine
MenABCWY (1 st gen) vaccine
Menveo liquid ³ vaccine
MMR (US) vaccine
Rotarix liquid (US) vaccine
RSV maternal* vaccine
RSV older adults* vaccine
gepotidacin* (2140944) uUTI and GC
sotrovimab* (VIR-7831) COVID-19
cabotegravir LA HIV PrEP
Blenrep* (anti-BCMA ADC) multiple myeloma
Jemperli* (PD-1 antagonist) solid tumours**
letetresgene-autoleucel*3 (3377794, NY-ESO-1 TCR) SS/MRCLS**
Zejula* (PARP inhibitor) ovarian & lung cancer**
AL001*4 (anti-sortilin) frontotemporal dementia5
Benlysta + Rituxan systemic lupus erythematosus
depemokimab* (LA anti-IL5 antagonist) asthma
Nucala COPD / nasal polyps
otilimab* (3196165, aGM-CSF inhibitor) rheumatoid arthritis**
daprodustat (HIF-PHI) anaemia in chronic kidney disease

Infectious Diseases HIV (ViiV) Oncology Immunology/Respiratory Opportunity Driven

Note: Only the most advanced indications are shown for each asset

*In-license or other alliance relationship with third party (Jemperli, cobolimab and LAG-3 are Tesaro assets); **Additional indications also under investigation; # GSK contributing pandemic adjuvant 1. In Phase 1/2 study 2. Transition activities underway to enable further progression by partner 3. In potentially registrational Ph2 trial 4. Pending Hart-Scott Rodino (HSR) clearance 5. Ph3 trial in patients with progranulin gene mutation NSCLC: non-small cell lung cancer; uUTI: uncomplicated urinary tract infection; GC: gonorrhea; SS: synovial sarcoma ; MRCLS: myxoid/round cell liposarcoma; PrEP: pre-exposure prophylaxis

Our R&D pipeline Upcoming late-stage milestones that will inform our progress



	2H 2021	2022
Regulatory decisions	Shingrix immuno-compromised Jemperli^ – dMMR/MSI-H solid tumors Nucala – nasal polyposis	cabotegravir – HIV PrEP; 1H 2022 MMR vaccine (US); mid 2022
Regulatory submissions		Blenrep DREAMM-3 – 3L+ multiple myeloma; 2H 2022 daprodustat ASCEND – anaemia in chronic kidney disease; 1H 2022 Jemperli RUBY ^{2^} – 1L endometrial cancer; 2H 2022 Rotarix (liquid US) – 1H 2022
Late-stage readouts	Phase 3: daprodustat ASCEND – anaemia in chronic kidney disease COVID-19 (Medicago) vaccine COVID-19 (Sanofi) vaccine Phase 2 otilimab OSCAR ¹ – severe COVID-19 related pulmonary disease sotrovimab COMET-PEAK –COVID-19 (IM)	Phase 3: sotrovimab COMET-TAIL – COVID-19 (IM); 1H 2022 gepotidacin EAGLE ² – uUTI; 1H 2022 Blenrep DREAMM-3 – 3L+ MM; 1H 2022 Blenrep DREAMM-8 – 2L+ MM; 2H 2022 Jemperli RUBY ^{2^} – 1L endometrial cancer; mid 2022 otilimab contRAst – rheumatoid arthritis; 2H 2022 MenABCWY vaccine; 2H 2022 RSV older adults vaccine; 2H 2022 RSV maternal vaccine; 2H 2022 Phase 2 bepirovirsen (HBV ASO) BE-CLEAR ³ – HBV; 1H 2022

- Ph2b data
- Late-stage defined as Phase 2b onwards IM: Intramuscular ^ Tesaro asset

Our R&D pipeline Changes in the portfolio since Q1 2021



New to Phase I	New to Phase II	New to Phase III	New to Registration
VIR-2482 ¹ (neutralizing monoclonal antibody) influenza AL101 ² (anti-sortilin monoclonal antibody) neurodegenerative disorders GSK'859 (EOS-448, TIGIT antagonist) cancer Klebsiella pneumoniae vaccine MenABCWY (2 nd gen) vaccine	GSK'109 (broadly neutralizing antibody) HIV S. Aureus vaccine	AL001 ² (anti-sortilin monoclonal antibody) FTD-GRN: frontotemporal dementia related to a mutation in the progranulin gene COVID-19 (Sanofi) vaccine Menveo liquid vaccine	MMR (US) vaccine
Removed from Phase I	Removed from Phase II	Removed from Phase III	Removed from Registration
	RSV paediatric vaccine feladilimab (3359609, ICOS agonist) solid tumors ³		Shingrix immuno-compromised (FDA approval)

- 1. Added to GSK pipeline as part of extended VIR collaboration with option for co-development after Ph2 completion
- 2. AL101 and AL001 pending HSR clearance
- 3. In Ph1 for combination with Blenrep in platform trial DREAMM-5